NEW YORK - Wyeth Inc. and several of its executive officers have agreed to pay more than $67 million to settle claims that they misrepresented the safety and approvability of the drug Pristiq in violation of federal securities laws, according to a motion for settlement filed Nov. 9 in New York federal court (City of Livonia Employees' Retirement System v. Wyeth Inc., et al., No. 07-10329, S.D. N.Y.). View related prior history, 2012 U.S. Dist. LEXIS 134854.